New HIV vaccine candidate enters early human testing
NCT ID NCT03934541
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new HIV vaccine in 24 healthy, HIV-negative adults. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus to the immune system. The main goal was to check if the vaccine is safe and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MPER-656 Liposome Vaccine
What this could lead to
If successful, this could pave the way for a vaccine that helps prevent HIV infection.
What could go wrong
This is a very early Phase 1 trial with only 24 people, focused on safety. It may not lead to an effective vaccine, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35294, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032-3732, United States
-
Fenway Health (FH) CRS
Boston, Massachusetts, 02215-4302, United States
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98109-1024, United States